Sign up
Pharma Capital

Allergy Therapeutics expects earnings to come in ahead of market expectations

Allergy Therapeutics PLC's (LON:AGY) CFO Nick Wykeman talks Proactive London's Andrew Scott through their trading update for the year to the end of June 2019.

He says net revenue for the year's expected to be £73.7mln, up 8% on last year, while cash at the end of June was £27.4mln.

That means the group has the funds to fully finance from existing resources the phase III clinical trial of its new short-form grass allergy inoculation due to start next autumn.


View full AGY profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.